Mirati Therapeutics, Inc.
MRTX
Rang in aandelen
#4885
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Aandeelprijs
$58.70
Laatst gesynchroniseerd: 2024-01-23
Marktkapitalisatie
$2.98B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Mirati Therapeutics, Inc. (MRTX)
Categorie
Healthcare
Koersgeschiedenis voor Mirati Therapeutics, Inc. (MRTX)
Hoogste slotkoers: $58.94 op 2024-01-01
Laagste slotkoers: $8.67 op 2013-07-01
Laagste slotkoers: $8.67 op 2013-07-01
Koersgeschiedenis van Mirati Therapeutics, Inc. van 2013 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2024 | 2.02% |
| 2023 | 12.06% |
| 2022 | -63.56% |
| 2021 | -39.15% |
| 2020 | 103.16% |
| 2019 | 189.49% |
| 2018 | 132.29% |
| 2017 | 218.41% |
| 2016 | -84.08% |
| 2015 | 98.82% |
| 2014 | 1.02% |
| 2013 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.48 | 7.66% |
CH
|
